Study authors disclose funding and industry roles with Theriva Biologics
- Disclosures from study investigators detail multiple funding sources and industry advisory roles spanning major pharmaceutical entities such as AstraZeneca, Bristol Myers Squibb, and Theriva Biologics.
- Evaluating complex viral vector therapies requires strict adherence to institutional protocols and specialized oncology oversight.
Trial Design and Therapeutic Rationale
Metastatic pancreatic ductal adenocarcinoma presents significant therapeutic hurdles due to a dense desmoplastic stroma that limits drug penetration. To address this structural barrier, researchers are investigating genetically modified viral vectors designed to replicate within tumor cells while expressing hyaluronidase, an enzyme that degrades extracellular matrix components. Investigators including B.L. and C.G.-P. report active clinical and research involvement with Theriva Biologics, the developer of the investigational oncolytic viral platform.
Investigator Disclosures and Industry Transparency
Comprehensive conflict of interest declarations associated with the study outline extensive industry engagement across the clinical team. Authors such as R.G.-C. report receiving honoraria, speaker fees, and research support from multiple pharmaceutical manufacturers including Astellas, Bayer, Sanofi, and Novartis. Similarly, R.P.C. and T.M. disclose advisory board memberships and institutional research funding from entities such as AstraZeneca, Ipsen, and Servier. Additional disclosures from E.J.K. and M. Hidalgo note stock ownership and consulting agreements with companies including Bristol Myers Squibb, Guardant Health, and Merck.
Several authors maintain direct operational ties to the commercial sponsor. C.L., S.C., M.K., M.A.S., A.M.B., L.A.R., V.J.W., C.B., and M. Cascallo are identified as current or former employees, stockholders, or patent holders associated with Theriva Biologics, holding intellectual property rights related to oncolytic viral therapy and antigen cross-reactivity frameworks.
Clinical Path Forward and Patient Guidance
For patients and families dealing with advanced pancreatic malignancies, coordinating care through specialized multidisciplinary oncology centers is essential for managing complex treatment regimens and assessing eligibility for emerging clinical investigations.
Disclaimer: The information provided in this article is for educational and scientific communication purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider regarding any medical condition, diagnosis, or treatment plan.